I feel the lack of future earnings guidance is holding the share price back. The lending growth seems to be increasing at a good rate, have tightened on expenses, and controlled bad debts.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025